Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2152-2168

  Reinhard, Emily J ^a,b   Wang, Jane L ^a   Durley, Richard C ^a   Fobian, Yvette M ^a   Grapperhaus, Margaret L ^a   Hickory, Brian S ^a   Massa, Mark A ^a   Norton, Monica B ^a   Promo, Michele A ^a   Tollefson, Michael B ^a   Vernier, William F ^a   Connolly, Daniel T ^a   Witherbee, Bryan J ^a   Melton, Michele A ^a   Regina, Karen J ^a   Smith, Mark E ^a   Sikorski, James A ^a,c  

^a PFIZER INC   (United States)

^b Alteon Inc   (United States)

^c AtheroGenies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[3 (3 ETHYLPHENOXY)PHENYL][3 (1,1,2,2 TETRAFLUOROETHOXY)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[3 (3 ISOPROPYLPHENOXY)PHENYL][3 (1,1,2,2 TETRAFLUOROETHOXY)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[3 (3 TRIFLUOROMETHOXYPHENOXY)PHENYL][3 (1,1,2,2 TETRAFLUOROETHOXY)BENZYL]AMINO] 1,1,1 TRIFLUORO 2 PROPANOL; 3 [[3 (4 CHLORO 3 ETHYLPHENOXY)PHENYL][2 FLUORO 4 (TRIFLUOROMETHYL)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[3 (4 CHLORO 3 ETHYLPHENOXY)PHENYL][2 FLUORO 5 (TRIFLUOROMETHYL)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[3 (4 CHLORO 3 ETHYLPHENOXY)PHENYL][3 (1,1,2,2 TETRAFLUOROETHOXY)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[3 (4 CHLORO 3 ETHYLPHENOXY)PHENYL][3 (PENTAFLUOROETHYL)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[3 (4 CHLORO 3 ETHYLPHENOXY)PHENYL][3 (TRIFLUOROMETHOXY)BENZYL]AMINO] 1,1,1 TRIFLUORO 2 PROPANOL; 3 [[3 (4 METHYLPHENOXY)PHENYL][3 (1,1,2,2 TETRAFLUOROETHOXY)BENZYL]AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; ALIPHATIC COMPOUND; ALKYL GROUP; ANILINE DERIVATIVE; BUFFER; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; ETHER DERIVATIVE; HALOGEN; HIGH DENSITY LIPOPROTEIN; HYDROGEN; LOW DENSITY LIPOPROTEIN; N [3 (1,1,2,2 TETRAFLUOROETHOXY)BENZYL] N (3 PHENOXYPHENYL)TRIFLUORO 3 AMINO 2 PROPANOL; PROTEIN INHIBITOR; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CHIRALITY; DRUG POTENCY; DRUG PURITY; DRUG SYNTHESIS; ELECTRON; ENANTIOMER; HUMAN; HYDROGEN BOND; IC 50; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PARTICULATE MATTER; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; ANTILIPEMIC AGENTS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CRICETINAE; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; MESOCRICETUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROPANOLAMINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038248837     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020528+     Document Type: Article

References (41)

1. Bruce, C.; Chouinard, R. A., Jr.; Tall, A. R. Plasma Lipid Transfer Proteins, High-Density Lipoproteins, and Reverse Cholesterol Transport. Annu. Rev. Nutr, 1998, 18, 297-330.
2. (a) Sikorski, J. A.; Connolly, D. T. The discovery of new cholesteryl ester transfer protein inhibitors. Curr. Opin. Drug Discovery Dev. 2001, 4, 602-613.
3. (b) Sikorski, J. A.; Glenn, K. C. Cholesteryl Ester Transfer Protein as a Potential Therapeutic Target to Improve the HDL to LDL Cholesterol Ratio. Annu. Rep. Med. Chem. 2000, 35, 251-260.
4. Hirano, K.-I.; Yamashita, S.; Matsuzawa, Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr. Opin. Lipidol. 2000, 11, 589-596.
5. Inazo, A.; Koizumi, J.; Mabuchi, H. Cholesteryl ester transfer protein and atherosclerosis. Curr. Opin. Lipidol. 2000, 11, 389-396.
6. Lagrost, L. Relationship of the Cholesteryl Ester Transfer Protein (CETP) to Athero-sclerosis. Adv. Vasc. Biol. 1999, 5 (Plasma Lipids and Their Role in Disease), 217-231.
7. Bruce, C.; Chouinard, R. A., Jr.; Tall, A. R. Plasma Lipid Transfer Proteins, High-Density Lipoproteins, and Reverse Cholesterol Transport. Annu. Rev. Nutr. 1998, 18, 297-330.
8. Yamashita, S.; Maruyama, T.; Hirano, K.-I.; Sakai, N.; Nakajima, N.; Matsuzawa, Y. Impairment of reverse cholesterol transport system and atherosclerosis. In Lipoprotein Metab. Atherog.; Kita, T.; Yokode, M., Eds. Springer-Verlag: Tokyo, Japan, 2000; pp 115-123.
9. Krause, B. R.; Auerbach, B. J. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr. Opin. Invest. Drugs 2001, 2, 375-381.
10. Tall, A. R.; Wang, N.; Mucksavage, P. Is it time to modify the reverse cholesterol transport model? J. Clin. Invest. 2001, 108, 1273-1275.
11. Zhang, Z.; Yamashita, S.; Hirano, K.; Nakagawa-Toyama, Y.; Matsuyama, A.; Nishida, M.; Sakai, N.; Fukasawa, M.; Arai, H.; Miyagawa, J.; Matsuzawa, Y. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis 2001, 159, 67-75.
12. Castelli, W. P.; Garrison, R. J.; Wilson, P. W.; Abbott, R. D.; Kalousdian, S.; Kannel, W. B. Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels. The Framingham Study. J. Am. Med. Assoc. 1986, 256, 2835-2838.
13. Kannel, W. B. Range of Serum Cholesterol Values in the Population Developing Coronary Artery Disease. Am. J. Cardiol. 1995, 76, 69c-77c.
14. Evans, G. F.; Bensch, W. R.; Apelgren, L. D.; Bailey, D.; Kauffman, R. F.; Bumol, T. F.; Zuckerman, S. H. Inhibition of Cholesteryl Ester Transfer Protein in Normocholesterol-emic and Hypercholesterolemic Hamsters: Effects on HDL Subspecies, Quantity, and Apolipoprotein Distribution. J. Lipid Res. 1994, 35, 1634-1645.
15. Sugano, M.; Makino, N.; Sawada, S.; Otsuka, S.; Watanabe, M.; Okamoto, H.; Kamada, M.; Mizushima, A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 1998, 273, 5033-5036.
16. (a) H, Yonemori, F.; Wakitani, K.; Minowa, T.; Maeda, K.; Shinkai, H. A Cholesteryl Ester Transfer Protein Attenuates Atherosclerosis in Rabbits. Nature 2000, 406, 203-207.
17. (b) Shinkai, H.; Maeda, K.; Yamasaki, T.; Okamoto, H.; Uchida, I. Bis[2-(acylamino)phenyl] disulfides, 2-(acylamino)benzenethiols, and S-[2-(acylamino)phenyl] alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J. Med. Chem. 2000, 43, 3566-3572.
18. Kobayashi, J.; Okamoto, Hiroshi; O. M.; Bujo, H.; Saito, Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low-density lipoprotein in J774 macrophage. Atherosclerosis 2002, 162, 131-135.
19. Koizumi, J.; Inazu, A.; Yagi, K.; Koizumi, I.; Uno, Y.; Kajinami, K.; Miyamoto, S.; Moulin, P.; Tall, A. R.; Mabuchi, H. Serum Lipoprotein Lipid Concentration and Composition in Homozygous and Heterozygous Patients with Cholesteryl Ester Transfer Protein Deficiency. Atherosclerosis 1991, 90, 189-196.
20. Ordovas, J. M.; Cupples, L. A.; Corella, D.; Otvos, J. D.; Osgood, D.; Martinez, A.; Lahoz, C.; Coltell, O.; Wilson, P. W. F.; Schaefer, E. J. Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk. The Framingham Study. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1323-1329.
21. De Grooth, J. G.; Kuivenhoven, J. A.; Stalenhoef, A. F. H.; de Graaf, J.; Zwinderman, A. H.; Posma, J. L.; van Tol, A.; Kastelein, J. J. P. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans. Circulation 2002, 104, 2159-2165.
22. Liu, S.; Schmitz, C.; Stampfer, M. J.; Sacks, F.; Hennekens, C. H.; Lindpaintner, K.; Ridker, P. M. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 2002, 161, 469-474.
23. Bruce, C.; Sharp, D. S.; Tall, A. R. Relationship of HDL and Coronary Heart Desease to a Common Amino Acid Polymorphism in the Cholesteryl Ester Transfer Protein in Men with and without Hyperalphalipoproteinemia. J Lipid. Res. 1998, 39, 1071-1078.
24. Agerholm-Larsen, B.; Tybjaerg-Hansen, A.; Schnohr, P.; Steffensen, R.; Nordestgaard, B. G. Common cholesteryl transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000, 102, 2197-2203.
25. Garber, K. Boosting "Good" Cholesterol. Mod. Drug Discovery 1999, 2, 67-75.
26. (a) Paulsen, H.; Antons, S.; Brandes, A.; Logers, M.; Muller, S. N.; Naab, P.; Schmeck, C.; Schneider, S.; Stoltefuss, J. Stereoselective Mukaiyama-Michael/Michael/Aldol Domino Cyclization as the Key Step in the Synthesis of Pentasubstituted Arenes: An Efficient Access to Highly Active Inhibitors of Cholesteryl Ester Transfer Protein (CETP). Angew. Chem., Int. Ed. 1999, 38, 3373-3375.
27. (b) Brandes, A.; Logers, M.; Stoltefuss, J.; Schmidt, G.; Bremm, K.-D.; Bischoff, H.; Schmidt, D.; Antons, S.; Paulsen, H.; Muller, S. N.; Naab, P.; Schmeck, C. Substituted Tetrahydronaphthalenes as Cholesteryl Ester Transfer Protein Inhibitors. WO9914174, March 25, 1999.
28. (a) Deninno, M. P.; Mangus-Aryitey, G. T.; Ruggeri, R. B.; Wester, R. T. Preparation of N-(1-Alkoxycarbonyl-1,2,3,4-Tetrahydroquinolin-4-yl)Carbamates as Cholesteryl Ester Transfer Protein Inhibitors. WO0017164, March 30, 2000.
29. (b) Deninno, M. P.; Mangus-Aryitey, G. T.; Ruggeri, R. B.; Wester, R. T. Preparation of 4-Amino Substituted 2-Substituted 1,2,3,4-Tetrahydroquinolines as CETP Inhibitors. WO0017165, March 30, 2000.
30. (c) Allen, D. J. M.; Appleton, T. A.; Brostrom, L. R.; Tickner, D. L. Preparation of (2R,4S)-4-[(3,5-bistri-fluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6- trifluoromethyl-3,4-di-hydro-2H-quinoline-1-carboxylic acid ethyl ester as CETP inhibitor. WO0140190, June 7, 2001.
31. (d) Damon, D. B. and Dugger, R. W. Method for making 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinolines. US6313142, November, 6, 2001.
32. (a) Durley, R. C.; Grapperhaus, M. L.; Massa, M. A.; Mischke, D. A.; Parnas, B. L.; Fobian, Y. M.; Rath, N. P.; Honda, D. D.; Zeng, M.; Connolly, D. T.; Heuvelman, D. M.; Witherbee, B. J.; Glenn, K. C.; Krul, E. S.; Smith, M. E.; Sikorski, J. A. Discovery of Chiral N,N-Disubstiuted Trifluoro-3-amino-2-propanols as Potent Inhibitors of Cholesteryl Ester Transfer Protein. J. Med. Chem. 2000, 43, 4575-4578.
33. (b) Durley, R. C.; Grapperhaus, M. L.; Hickory, B. S.; Massa, M. A.; Wang, J. L.; Spangler, D. P.; Mischke, D. A.; Parnas, B. L.; Fobian, Y. M.; Rath, N. P.; Honda, D. D.; Zeng, M.; Connolly, D. T.; Heuvelman, D. M.; Witherbee, B. J.; Glenn, K. C.; Krul, E. S.; Smith, M. E.; Sikorski, J. A.Chiral N,N-Disubstiuted Trifluoro-3-amino-2-propanols are Potent Inhibitors of Cholesteryl Ester Transfer Protein. J. Med. Chem. 2002, 45, 3891-3904.
34. Connolly, D. T.; Witherbee, B. J.; Melton, M. A.; Durley, R. C.; Grapperhaus, M. L.; McKinnis, B. R.; Vernier, W. F.; Babler, M. A.; Shieh, J.-J.; Smith, M. E.; Sikorski, J. A. Stereospecific Inhibition of CETP Activity by Chiral N,N-Disubstituted Trifluoro-3-Amino-2-propanols. Biochemistry 2000, 39, 13870-13879.
35. Hartwig, J. F. Carbon-Heteroatom Bond-Forming Reductive Elimination of Amines, Ethers and Sulfides. Acc. Chem. Res. 1998, 31, 852-860.
36. Marcoux, J.-F.; Doye, S.; Buchwald, S. L. A General Copper-Catalyzed Synthesis of Diaryl Ethers. J. Am. Chem. Soc. 1997, 119, 10539-10540.
37. Marcoux, J.-F.; Doye, S.; Buchwald, S. L. Preparation of Diaryl Ethers and Related Compounds by Condensation reactions Using Transition metal Complex Catalysts. WO9918057, April 15, 1999.
38. Ramachandran, P. V.; Gong, B.; Brown, H. C. Chiral Synthesis via Organoboranes. 40. Selective Reductions. 55. A Simple One-Pot Synthesis of the Enantiomers of Trifluoro-methyloxirane. A General Synthesis in High Optical Purities of α-Trifluoromethyl Secondary Alcohols via the Ring-Cleavage Reactions of the Epoxide. J. Org. Chem. 1995, 60, 41-46.
39. 3H]CE)-HDL donor particles could be measured in the presence of human serum, which provided the source of the LDL, VLDL, and human CETP as described in detail in ref 27.
40. Massa, M. A.; Spangler, D. P.; Durley, R. C.; Hickory, B. S.; Connolly, D. T.; Witherbee, B. J.; Smith, M. E.; Sikorski, J. A. Novel Heteroaryl Replacements of Aromatic 3-Tetrafluoroethoxy Substituents in Trifluoro-3-(tertiaryamino)-2-propanols as Potent Inhibitors of Cholesteryl Ester Transfer Protein. Bioorg. Med. Chem. Lett. 2001, 11, 1625-1628.
41. Hope, H. R.; Heuvelman, D.; Duffin, K.; Smith, C.; Zablocki, J.; Schilling, R.; Hegde, S.; Lee, L.; Witherbee, B.; Baganoff, M.; Bruce, C.; Tall, A. R.; Krul, E.; Glenn, K.; Connolly, D. T. Inhibition of cholesteryl ester transfer protein by substituted dithiobis-nicotinic acid dimethyl ester: involvement of a critical cysteine. J. Lipid Res. 2000, 41, 1604-1614.